NASDAQ:ARTL

Artelo Biosciences Q1 2026 Earnings Results & Report

Artelo Biosciences logo
$1.35 -0.10 (-6.97%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.37 +0.02 (+1.26%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artelo Biosciences missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$36.00 versus the -$7.02 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Artelo Biosciences EPS Results

Actual EPS
-$36.00
Consensus EPS
-$7.02
Beat/Miss
Missed by -$28.98
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Q1 2026 Earnings FAQ

Artelo Biosciences (NASDAQ:ARTL) reported earnings of -$36.00 per share for Q1 2026, missing the consensus estimate of -$7.02. The report was announced on Thursday, May 14, 2026.

Artelo Biosciences Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain.

The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation.

Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.

View Artelo Biosciences Profile